Company intelligence / Profile preview

Commave Therapeutics

Genève, Geneva, Switzerland

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Commave Therapeutics holds ex-US rights to AZSTARYS (serdexmethylphenidate + dexmethylphenidate), a once-daily ADHD therapy approved by the FDA in 2021; the drug is commercially available in the US through Corium and being out-licensed in other regions (e.g., to Ark Biopharmaceutical for Greater China), but clinical results beyond regulatory approval are not detailed in available sources[1][3][4].

Therapeutic areas: Psychiatry
Modalities: Small molecule
Industry: Biotech

Partnerships

Ark Biopharmaceutical (AZSTARYS outlicense in Greater China)Corium (US commercialization of AZSTARYS, GPC affiliate)

Beyond the preview

Go deeper on Commave Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Commave Therapeutics.

Explore the full profile